Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma

Clear cell, mesenchymal, and dedifferentiated chondrosarcoma are rare, cartilaginous tumors with limited treatment options other than surgery. Conventional chondrosarcomas have been extensively studied at the genetic level, but for rare chondrosarcoma subtypes, this is merely restricted to case reports. Information on the genetics of rare chondrosarcomas may provide insight into the etiology of these specific disease subtypes and possible alternative treatment strategies. Therefore, the aim of this study was to genetically characterize this subset of rare tumors. Using array CGH, we gathered genomic information of 30 rare cartilaginous tumors. In addition, we constructed tissue microarrays with 2 mm cores of 23 clear cell, 23 mesenchymal, and 45 dedifferentiated chondrosarcomas, in triplicate. Using immunohistochemistry, we investigated expression of R132H IDH1, and p53 and retinoblastoma pathways. Results were verified and further investigated with a methylation assay and MLPA for CDKN2A/p16, and IDH1/2, and TP53 mutation analysis. Array‐CGH showed numerous genomic alterations in all subtypes. However, only a limited number of recurrent alterations were detected, none of which seemed to be associated with the subtypes. The IDH1/2, p53, and retinoblastoma pathways were affected in 0, 9, and 95% of clear cell chondrosarcomas, in 0, 39, and 70% in mesenchymal chondrosarcomas, and in 50, 59, and 85% of dedifferentiated chondrosarcomas, respectively. Our results suggest an important role for the retinoblastoma pathway in all three rare chondrosarcoma subtypes investigated. © 2012 Wiley Periodicals, Inc.

[1]  S. Larsson,et al.  Chondrosarcoma , 2004, International Orthopaedics.

[2]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[3]  M. Romsdahl,et al.  Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading , 1977, Cancer.

[4]  A. Cohn.  Bone tumors. , 1978, Orthopedics.

[5]  C. Povỳsil,et al.  [Clear cell chondrosarcoma]. , 1982, Ceskoslovenska patologie.

[6]  G. Rosen,et al.  Mesenchymal chondrosarcoma a clinicopathologic analysis of 35 patients with emphasis on treatment , 1983, Cancer.

[7]  W. Wierzchowski,et al.  [Mesenchymal chondrosarcoma]. , 1983, Patologia polska.

[8]  F. Sim,et al.  Clear cell chondrosarcoma of bone: Observations in 47 cases , 1984, The American journal of surgical pathology.

[9]  M. Mercuri,et al.  Dedifferentiated chondrosarcoma , 1988, The Journal of bone and joint surgery. American volume.

[10]  W. Couser,et al.  Urinary excretion of C5b-9 reflects disease activity in passive Heymann nephritis. , 1989, Kidney international.

[11]  P. Picci,et al.  Clear cell chondrosarcoma of bone. A report of 8 cases. , 1991, Skeletal radiology.

[12]  H. Kroon,et al.  Radiologic Atlas of Bone Tumors , 1993 .

[13]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[14]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[15]  R. Hruban,et al.  Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.

[16]  D. Sidransky,et al.  Rates of p16 (MTS1) mutations in primary tumors with 9p loss. , 1994, Science.

[17]  B. Coughlan,et al.  p53 expression and DNA ploidy of cartilage lesions. , 1995, Human pathology.

[18]  S. Knuutila,et al.  Gains, losses, and amplifications of DNA sequences evaluated by comparative genomic hybridization in chondrosarcomas. , 1997, The American journal of pathology.

[19]  D. Louis,et al.  CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. , 1998, The American journal of pathology.

[20]  R. Grimer,et al.  Clear Cell Chondrosarcoma of Bone , 1999, Sarcoma.

[21]  A. Cleton-Jansen,et al.  Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis , 1999, The Journal of pathology.

[22]  A. Lindahl,et al.  Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues , 2000, International journal of cancer.

[23]  R. Schneider-Stock,et al.  Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma , 2000, Virchows Archiv.

[24]  P. Cin,et al.  Chromosome 9 alterations and trisomy 22 in central chondrosarcoma: a cytogenetic and DNA flow cytometric analysis of chondrosarcoma subtypes. , 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[25]  J. Block,et al.  Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma , 2001, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[26]  C. Denny,et al.  Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation , 2001, Oncogene.

[27]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[28]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[29]  P. D. Dal Cin,et al.  Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group , 2002, The Journal of pathology.

[30]  R. Schneider-Stock,et al.  Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma. , 2003, Pathology, research and practice.

[31]  R. Sciot,et al.  Molecular analysis of the INK4A/INK4A‐ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression , 2004, The Journal of pathology.

[32]  L. Kindblom,et al.  Clear-cell chondrosarcoma , 2004, Virchows Archiv A.

[33]  J. Nishio,et al.  Cytogenetic findings in clear cell chondrosarcoma. , 2005, Cancer genetics and cytogenetics.

[34]  H. Tanke,et al.  Array‐comparative genomic hybridization of central chondrosarcoma , 2006, Cancer.

[35]  M. A. van de Wiel,et al.  CGHregions: Dimension Reduction for Array CGH Data with Minimal Information Loss , 2007, Cancer informatics.

[36]  Wessel N. van Wieringen,et al.  CGHregions: Dimension Reduction for Array CGH Data with Minimal Information Loss , 2007 .

[37]  H. Tanke,et al.  EWSR1-CREB1 and EWSR1-ATF1 Fusion Genes in Angiomatoid Fibrous Histiocytoma , 2007, Clinical Cancer Research.

[38]  Samuel Myllykangas,et al.  CanGEM: mining gene copy number changes in cancer , 2007, Nucleic Acids Res..

[39]  M. A. van de Wiel,et al.  Weighted clustering of called array CGH data. , 2008, Biostatistics.

[40]  J. Blay,et al.  Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors , 2009, Clinical Cancer Research.

[41]  S. Knuutila,et al.  Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors , 2009, Clinical Cancer Research.

[42]  Paul H. C. Eilers,et al.  MLPAinter for MLPA interpretation: an integrated approach for the analysis, visualisation and data management of Multiplex Ligation-dependent Probe Amplification , 2009, BMC Bioinformatics.

[43]  P. Hogendoorn,et al.  Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes , 2009, Modern Pathology.

[44]  A. Scarpa,et al.  Pathology and Genetics , 2010 .

[45]  A. Cleton-Jansen,et al.  Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma , 2010, Genes, chromosomes & cancer.

[46]  P. Hogendoorn,et al.  Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples , 2011, BMC Research Notes.

[47]  A. Cleton-Jansen,et al.  Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo , 2011, Clinical Sarcoma Research.

[48]  R. Sciot,et al.  Somatic mosaic IDH1 or IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome , 2011, Nature Genetics.

[49]  A. Grigoriadis,et al.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.

[50]  N. Socci,et al.  Identification of a novel, recurrent HEY1‐NCOA2 fusion in mesenchymal chondrosarcoma based on a genome‐wide screen of exon‐level expression data , 2012, Genes, chromosomes & cancer.

[51]  A. Flanagan,et al.  IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas , 2012, Histopathology.

[52]  D. Jong,et al.  Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT , 2012, Oncogene.